NTAGI to meet this week to introduce ZycoV-D in COVID-19 vaccination plan

Indian made Zydus Cadila Covid Vaccine ZyCoV-D has received approval for emergency use authorization from DCGI.  (File photo/Reuters)

Indian made Zydus Cadila Covid Vaccine ZyCoV-D has received approval for emergency use authorization from DCGI. (File photo/Reuters)

The meeting will also look at the priority of the beneficiaries as the vaccine has been approved for both adolescents and adults.

  • CNN-News18
  • Last Update:Aug 25, 2021, 2:37 PM IS
  • Follow us on:

The National Technical Advisory Group on Immunization will hold an important meeting this week to outline a roadmap for introducing the DNA-based Zydus Cadila vaccine to the general public.

It is expected that this meeting will help in formulating a plan on how to include and introduce the ZycoV-D vaccine in India’s immunization programme.

It will also look at the preference of the beneficiaries as the vaccine has been approved for both adolescents and adults.

According to a top government official, there are over 120 million adolescents in the age group of 12 to 18 years in India and about 1% of adolescents in the age group of 12 to 18 years are susceptible to severe COVID19 infection.

The official said priority would be given to adolescents with comorbidities while the three-dose vaccine would be introduced in the general population first.

The needle-free Zycov-D vaccine got emergency use authorization from DCGI on August 20 and will be introduced in the vaccination schedule in the coming 4-5 weeks, according to sources. NTAGI will provide the framework for immunization of the Covid-19 vaccine.

The world’s first plasmid DNA vaccine will be administered in a three-dose regimen, administered via a needle-free system on days zero, 28 and 56.

The Ahmedabad-based company had earlier said it expected to introduce 10 million doses per month from October.

read all breaking newshandjob breaking news And coronavirus news Here

.

Leave a Reply